Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.37 |
| ▸ | PPARG | P37231 | 6/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27332213 | 1.00 | RORC (0.37) | RORCPPARGS1PR5S1PR1AR | |
| SCHEMBL30723583 | 0.90 | SMN1; SMN2 (0.42) | ALKBH1SMN1; SMN2ITGA4NR1H4MAPT | |
| SCHEMBL27333082 | 0.90 | SMN1; SMN2 (0.42) | ALKBH1SMN1; SMN2ITGA4NR1H4MAPT | |
| SCHEMBL27332105 | 0.88 | CYP3A4 (0.36) | RORCPPARGMAPT | |
| SCHEMBL30723723 | 0.88 | ALKBH1 (0.44) | RORCPPARGS1PR5S1PR1AR | |
| SCHEMBL27332103 | 0.88 | ALKBH1 (0.44) | RORCPPARGS1PR5S1PR1AR | |
| SCHEMBL30723600 | 0.87 | RORC (0.39) | RORCPPARGS1PR5S1PR1AR | |
| SCHEMBL27331972 | 0.87 | RORC (0.39) | RORCPPARGS1PR5S1PR1AR | |
| SCHEMBL27333077 | 0.86 | HDAC1 (0.31) | — | |
| SCHEMBL30723665 | 0.85 | RORC (0.36) | RORCPPARGS1PR5S1PR1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4532487-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | Sanofi US Services Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119301115-A | Compounds for enhancing read-through of genes containing premature stop codons and methods of making and using the same | 赛诺菲美国服务公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023235384-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | UPF1, NUDT21, RNGTT | RORC 3867/4885PPARG 2573/4885S1PR5 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.